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We review the rationale behind the statistical design of dose-finding studies as used in phase I and phase I/II clinical trials. We
underline what the objectives of such dose-finding studies should be and why the widely used standard design fails to meet any of
these objectives. The standard design is a ‘memoryless’ design and we discuss how this impacts on practical behaviour. Designs
introduced over the last two decades can be viewed as designs with memory and we discuss how these designs are superior to
memoryless designs. By superior we mean that they require less patients overall, less patients to attain the maximum tolerated dose
(MTD), and concentrate a higher percentage of patients at and near to the MTD. We reanalyse some recently published studies in
order to provide support to our contention that markedly better results could have been achieved had a design with memory been
used instead of a memoryless design.
British Journal of Cancer (2006) 94, 609–613. doi:10.1038/sj.bjc.6602969 www.bjcancer.com
Published online 24 January 2006
& 2006 Cancer Research UK
Keywords: clinical trial; continual reassessment method; dose escalation; dose-finding studies; maximum tolerated dose; phase1 trial;
toxicity
                                         
There is an average of 10 years between the development of
improved statistical methods and their implementation in practice.
In the area of phase I dose-finding studies, this average is exceeded
since a review of the literature indicates that most current studies
are being carried out according to statistical designs, which are
over half a century old. Furthermore, it had been demonstrated
that these old designs are inefficient and inferior to new designs
published in the literature since the late nineteen eighties.
The old (although still currently widely used) designs can be
described as memoryless designs as opposed to the majority of
the new ones, which can be labelled as designs with memory. In
the following sections, we clarify just what we mean by the term
‘memoryless’. Following this we describe designs with memory and
the advantages, which follow from such a property. Finally, we
consider several recently published studies and indicate how we
could have performed better had more efficient designs been
used. Firstly, we recall the basic principles of phase I dose-finding
studies, in particular in the context of cytotoxic agents.
BACKGROUND
For cytotoxic anticancer drugs, it is assumed that there exists a
dose–toxicity effect whereby the higher the dose, the greater the
risk of observing dose-limiting toxicity. The goal of dose-finding
studies is to find the highest tolerable dosage: the maximum
tolerated dose (MTD) that corresponds to some given acceptable
toxicity rate. In studies of treatment efficacy, similar methodology
is employed aiming to identify a dose capable of producing a given
rate of success. A model that is widely assumed for cytotoxics,
although (as for any model) open to debate, is a model that
assumes monotonicity. This means that when a patient experi-
enced a dose-limiting toxicity at a specific level, then, had this
same patient been treated at any higher level he would also have
suffered dose-limiting toxicity. Conversely, were the patient to
tolerate the treatment at a specific dosage, then, for all lower levels,
the patient would also have tolerated treatment. This is reasonable
in most cases but might need to be questioned in certain
situations, for example, for immunological therapies. Figure 1
illustrates three such dose toxicity curves for three hypothetical
patients. Owing to patient variability, each patient responds at a
different level. Some patients are able to tolerate higher levels of
treatment than others. Most often we will not be able to know for
any individual just what their particular dose toxicity (0, 1) step
function might be; in other words, the lowest level at which the
patient would encounter a dose-limiting toxicity. However, we can
learn this for a group of subjects. In the light of patient variability,
the lowest level for one patient may differ from that for another.
Were we to take an average over the three patients, we would have
a step function with steps of size 1/3 at the observed change points.
Were we to target a level where 33% of subjects encounter a DLT,
then we could estimate a point above dose d3 and below dose d4.
This would of course be a rough estimate, since three patients
may not be enough to capture the effects of a much larger group.
However, as we include bigger samples, we can conceive of the
simple step function for three patients becoming more refined and
eventually looking something like Figure 2. In practice, we will not
know such a curve and the problem is to find the dose di such that
some given percentage of patients will encounter a DLT at this
dose and higher doses. Technically, our problem is to inverse the
curve in Figure 2. This inversion would tell us which dose
corresponds to some given rate of toxicity.
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The precise goals of a phase I dose-finding study are not always
clearly defined. The absence of such definitions and the lack of
clinically motivated exigencies have led to the use of a number of
schemes, in particular the standard design, having properties that
are clearly undesirable. We call such designs ‘memoryless’ and we
describe them in the next section. It was argued (O’Quigley et al,
1990) that the clinical requirements of a phase I dose-finding study
should be to the following:
1. minimize the number of under-treated patients, that is, patients
treated at unacceptably low-dose levels;
2. minimize the number of overtreated patients, that is, patients
treated at unacceptably high-dose levels;
3. minimize the number of patients needed to complete the study
(efficiency); and
4. respond quickly to inevitable errors in initial guesses, rapidly
escalating in the absence of indication of drug activity (toxicity)
and rapidly de-escalating in the presence of unacceptably high
levels of observed toxicity.
The reason argued that we need to consider accepting toxicity
in phase I cancer studies is because, without some toxicity, we will
not see any efficacy and vice versa. Indeed, it is common in this
context to view toxicity as a surrogate for efficacy. The question
then is how to control for the amount of toxicity. In the light of
these observations, the goal of a phase I study of cytotoxics is to
identify a target dose level at which the rate of toxicity is as close as
possible to some predetermined rate, typically 20–30%. The goal
is to identify this level at the end of the study but also, during
the study itself, to concentrate as many patients as possible at and
around this target level. Designs with memory achieve this goal.
Memoryless designs do not.
MEMORYLESS DESIGNS
The standard design is a memoryless design. This includes three
patients at the lowest dose level. If all three patients tolerate the
dose, then a further three patients are included at the dose
immediately above the lowest level. This is continued until a DLT
is encountered. If there are two or more of these in the group of
three patients then the dose is considered unacceptable and a
further three patients are included at the level just below this. If no
more than one toxicity is encountered among that group of three
patients, then this level is recommended as the MTD. Otherwise,
we descend a further level until this is the case, in which case the
level is then defined as the MTD.
The standard design is a so-called random walk that incorpo-
rates a stopping rule. The stopping rule brings the study to a halt
as soon as two or more toxicities have been observed at a level and,
for all levels below this, we define the MTD as the highest level at
which we observe no more than one toxicity out of a total of six
patients. There are a number of variants upon this scheme, but
they all share an essential property; allocation to the next dose level
for an incoming group of three patients only depends upon what
has happened to the total of six patients treated at that level. All
other information concerning other dose levels and the distribu-
tion of toxicities are ignored. Thus the information is lost. These
designs are in consequence memoryless.
This is a serious shortcoming and has been pointed out by
several authors (Faries, 1994; Korn et al, 1994; Goodman et al,
1995). In more involved situations, things get worse. Take, for
instance, the two group case, a case that arises frequently, possibly
in the majority of studies. A common example arises when we have
one group defined as having received relatively heavy prior
treatment and a second group having relatively less prior
treatment. We anticipate the first of these groups to have an
MTD no greater than that for the second group. Yet, for the
standard design, there is no way to use this information. Parallel
studies need to be run and what happens in one group has no
impact on treatment allocation for the other.
DESIGNS WITH MEMORY
The main idea to designs with memory leans on a fundamental
statistical principle -all the information should be used. As the
study progresses and new patients are included, then our estimate
of the MTD becomes more precise. The most well-known design
with memory is the continual reassessment method (CRM)
(O’Quigley et al, 1990). The basic idea is to directly address the
first two requirements for phase I studies, outlined above; (1) we
should minimize the number of undertreated patients, that is,
patients treated at unacceptably low-dose levels and (2) we should
minimize the number of patients treated at unacceptably high-dose
levels. The MTD can then be viewed as the level such that, above it
we are overtreating, below it we are undertreating. We would aim
to treat as many patients as possible at the MTD. The essential
nature of the CRM (Gasparini and Eisele, 2000) is:
1. an allocation rule to assign sequentially the incoming patients
to one of the possible doses, with the intent of assigning doses
ever closer to, and eventually recommending, the MTD;
2. a statistical procedure that updates the information on the
probabilities of toxicity in light of the results obtained for the
patients already observed.
Apart from the dose levels we can assume, for the simplest
designs the only observation we will make will be whether or not
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Figure 2 Dose toxicity curve for a hypothetical population of patients.
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as a surrogate for efficacy; the level is high enough for producing
some treatment effect. Of course we do not have two types of DLT,
toxicity DLT and an efficacy DLT. We only have one and this
leads us to consider some rate of observation of DLT as being
satisfactory. We consider that there exists some level, among those
available, producing a rate of DLTs such that significantly higher
rates would be viewed as being too toxic, and significantly lower
rates would be viewed as producing insufficient response.
The level producing this satisfactory rate is called the target
level, or the MTD. There is some arbitrariness in the choice of this
rate, and input from the clinicians is needed. The older standard
design was based largely upon the idea of escalating to a level
where we observe, on average, one DLT in three patients, a level
considered too toxic, so that the MTD was taken to be the level just
below this, resulting in one DLT in four patients or one DLT in five
patients. These rates 0.33, 0.25 and 0.2 are those most commonly
used in phase I studies. Apart from practical considerations,
nothing prevents the investigator from working with other rates.
Once the investigators have decided upon an acceptable target
rate, the MTD is then defined to be the level producing a rate of
toxicity as close as possible to this rate. The aim of the continual
reassessment method is not only to identify such a level but, in the
light of all available information, to treat each included patient at
our best guess of this level. Each patient adds to this information,
hence the term ‘reassessment’. The important idea is that of
updating whatever information we have after each observation or
group of observations.
Worked illustration
In order to be able to treat each included patient at the level
producing a rate of DLTs closest to some, acceptable, target rate.
which we denote as y, we need estimates of the DLT rate at each
dose. There were six dose levels, denoted d1 to d6. The unknown
probability of toxicity of observing a DLT at dose level di is
denoted by R(di), for i taking values from 1 to 6. Our problem is to
estimate R(d1)t oR(d6) in the light of observations made. We will
use a simple working model, to carry out this estimation. Our
working model is chosen such that our estimates R ˆ(di) of the
unknown R(d1)oR(d2) oo R(d6) and R(d1)oR(d2)oyoR(d6)
as well as R ˆ(d1)oR ˆ(d2) oo R ˆ(d6). In this computer illustration,
the true toxic probabilities were R(d1)¼0.03, R(d2)¼0.22,
R(d3)¼0.45, R(d4)¼0.60, R(d5)¼0.80 and R(d6)¼0.95, these
probabilities being unknown. The target toxicity rate was chosen
to be y¼0.20 (O’Quigley and Shen, 1996). The MTD is then dose
level 2 where the true toxicity probability is 0.22. As an aside, the
most effective CRM designs are so called two-stage designs; an
early escalation stage followed by a CRM guided modelling stage.
Following an initial escalation strategy mimicking the standard
design, we have the following observations on nine patients;
  level 1: 0 toxicities/three patients,
  level 2: 0 toxicities/three patients,
  level 3: 2 toxicities and one non-toxicity/three patients.
On the basis of our model we have, R ˆ(d1)¼0.101, R ˆ(d2)¼0.149,
R ˆ(d3)¼0.316, R ˆ(d4)¼0.472, R ˆ(d5)¼0.652 and R ˆ(d6)¼0.775. The
10th entered patient is then treated at level 2 for which
R ˆ(d2)¼0.149 since, from the available estimates, this is the closest
to the target y¼0.20. The 10th included patient does not suffer
toxic effects and, as a result, all our probability estimates are
revised downward, only very slightly since such an observation
does not contain much information. We now estimate the six
probabilities of toxicity as;
R ˆ(d1)¼0.070, R ˆ(d2)¼0.133, R ˆ(d3)¼0.295, R ˆ(d4)¼0.451,
R ˆ(d5)¼0.635, and R ˆ(d6)¼0.763. Once again the level that turns
out to have an estimated probability of toxicity the closest to
y¼0.20 is level 2. Thus the 11th included patient is treated at level
2. Continuing in this way, it turns out that this same level, level 2,
is in fact recommended to all of the remaining patients. After the
inclusion of 16 patients, the recommended MTD is then level 2.
The estimated probability of toxicity at this level is 0.212 and a
90% confidence interval for this probability is estimated as
(0.07, 0.39).
MEMORYLESS DESIGNS VS DESIGNS WITH MEMORY
The main perceived advantages of the standard design are
threefold; its simplicity, its conservativeness in terms of cautious
escalation and its ability to provide a reliable recommendation by
using few patients. The first of these is true. The other two are
not. These latter perceived advantages require closer scrutiny.
Although it is very possible for the standard design to come to a
conclusion by using few patients, there is a high cost, which
accompanies this in that, corresponding to the small number of
patients, the probability of an incorrect recommendation is
unacceptably high (Reiner et al, 1999; Levy et al, 2001). Via
simulations, those authors demonstrated that across a broad class
of plausible situations, should the trial terminate after less than 16
patients, then the probability of correctly identifying the MTD
would rarely exceed 20%, a performance that can only be described
as lamentable.
SOME RECENTLY PUBLISHED STUDIES REVISITED
Simulations, under a very wide array of possible situations, show
that designs with memory, in particular the continual reassessment
method, do better than memoryless designs. By ‘better’ we mean
that they reach the MTD more quickly and that they treat more
patients at and close to the MTD. The hypothetical aspect to
simulations, although convincing enough for statisticians familiar
with such tools, will sometimes leave the clinician sceptical. For a
trial completed using a standard design, the clinician will often
ask: what would the CRM or some other design with memory have
performed had it been employed. It is not possible to provide an
unequivocal answer to this question since, had a dynamic design
with memory been used, the distribution of visited dose levels
would generally change and we cannot know for certain what the
responses at these levels would have been. However, following
O’Quigley (2005), we are in a position to reanalyse completed real
studies and, although we can not provide a fully determined
answer to the question, we can provide useful estimates of the
MTD that would have been identified by the competing design
(given the data at hand and not simulated data) as well as dose
levels visited during the study. While not giving an unqualified
answer to the question (as no such answer exists), a retrospective
analysis does throw further light on how we might expect to have
performed had a design with memory been used in a number of
recent studies.
The lurtotecan trial
In this study, six different dose levels of lurtotecan were studied,
namely, 1.5, 2.2, 3.3, 3.7, 4.0 and 4.9mgm
 2 (Giles et al, 2004). A
total of 20 patients were included in the trial of which two (10%)
patients were at dose level 1, 2 patients (10%) at dose level 2, 2
(10%) patients at dose level 3, 6 (30%) patients at dose level 4, 6
(30%) patients at dose level 5 and 2 (10%) patients at dose level 6.
Table 1 represents the administered dose levels and the observed
DLTs. At the end of the trial, the estimated MTD was 3.7mgm
 2.
We applied a retrospective analysis on those data using the CRM
(O’Quigley, 2005). The MTD is identified as level 4 using both the
standard design and the CRM. The important observation to make
is that the CRM would have included nearly 50% of the patients at
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standard design. And this would have been a yet poorer figure had
the investigators respected the protocol of 3 3 inclusions. As can
be seen from the table, the early inclusions proceeded in groups of
2. Another important observation to be made is the percentage
treated far from the MTD, either above or below. By far from the
MTD, we mean by more than one level away from the MTD. 10%
of patients were treated at level 6 using the standard design as
opposed to 2% using the CRM. Such an observation confirms
the simulation findings of earlier work (Korn et al, 1994). Of the
patients, 20% were treated at levels 1 and 2 using the standard
design as opposed to the figure of 15% using the CRM.
The AMD473 and docetaxel trial
In this study 4 different dose levels of AMD473 and docetaxel were
studied, namely, 80/60, 80/75, 100/75 and 120/75mgm
 2 of
AMD473 and mgm
 2 of docetaxel (Gelmon et al, 2004). A total
of 33 patients were included in which eight (24%) patients at dose
level 1, six patients (18%) at dose level 2, nine (27%) patients at
dose level 3 and 10 (30%) patients at dose level 4 (Table 1). At the
end of the trial the estimated MTD was 120/75mgm
 2.O n
applying a retrospective analysis on those data, the recommended
dose level, once again, turns out to be the same. As for the
preceding example, the allocation probabilities were considerably
better under the CRM than the standard design. A total of 53% of
patients would have received the MTD as opposed to the 30%
under the standard design.
The topotecan trial
A phase I dose finding study aiming to identify the MTD of
intraperitoneal topotecan in combination with intravenous car-
platin and paclitaxel in advanced ovarian cancer was described
(Bos et al, 2005). Four different dose levels of topotecan were
studied, 10, 15, 20 and 25mgm
 2. In this trial, 21 patients were
included in which three (14%) patients at dose level 1, seven
patients (33%) at dose level 2, six (28%) patients at dose level 3
and five (24%) patients at dose level 4 (Table 1). At the end of the
trial, the estimated MTD was 20mgm
 2. Applying a retrospective
analysis to these data, we found the recommended dose level to be
again 20mgm
 2. From our simulation study, if a CRM design had
been used, the MTD would have been administered to 51% of the
patients, which is substantially better than the 28% receiving the
MTD under the standard design, which was actually used.
The amrubicin trial
Okamoto et al (2006) describe a phase I dose-finding trial of
amrubicin in patients with refractory or relapsed lung cancer.
Three different dose levels of amrubicin were studied, namely, 30,
35 and 40mgm
 2. In this trial 15 patients were included in which
six (40%) patients at dose level 1, six patients (40%) at dose level 2
Table 1 Dose-escalation and retrospective analysis
The lurtotecan trial
Dose (mgm
 2) 1.5 2.2 3.3 3.7 4.0 4.9
No. of patients 2 2 2 6 6 2
No. of patients with DLT 0 0 0 2 3 2
Estimated probabilities of toxicity from the data 0 0 0 0.33 0.5 1
Relative frequencies of allocation 0.1 0.1 0.1 0.3 0.3 0.1
Retrospective analysis
Mean relative frequencies of allocation using CRM 0.05 0.1 0.13 0.49 0.21 0.02
Recommended dose level using retrospective CRM X
The AMD473 and docetaxel trial
Dose (mgm
 2–mgm
 2) 80/60 80/75 100/75 120/75
No. of patients 8 6 9 10
No. of patients with DLT 1 1 2 3
Estimated probabilities of toxicity from the data 0.125 0.17 0.22 0.30
Relative frequencies of allocation 0.24 0.18 0.27 0.30
Retrospective analysis
Mean relative frequencies of allocation using CRM 0.07 0.16 0.22 0.53
Recommended dose level using retrospective CRM X
The topotecan trial
Dose(mgm
 2)1 0 1 5 2 0 2 5
No. of patients 3 7 6 5
No. of patients with DLT 0 1 1 3
Estimated probabilities of toxicity from the data 0 0.14 0.17 0.6
Relative frequencies of allocation 0.14 0.33 0.28 0.24
Retrospective analysis
Mean relative frequencies of allocation using CRM 0.08 0.22 0.51 0.19
Recommended dose level using retrospective CRM X
The amrubicin trial
Dose (mgm
 2)3 0 3 5 4 0
No. of patients 6 6 3
No. of patients with DLT 1 2 3
Estimated probabilities of toxicity from the data 0.17 0.33 1
Relative frequencies of allocation 0.4 0.4 0.2
Retrospective analysis
Mean relative frequencies of allocation using CRM 0.33 0.6 0.07
Recommended dose level using retrospective CRM X
X¼the recommended dose level.
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the trial, the recommended dose was 35mgm
 2. On applying a
retrospective analysis on those data, the recommended dose level
was once again the same, that is, 35mgm
 2 a dose to which, we
would have administered the MTD in 60% of the patients unlike
the 40% obtained using the standard analysis.
TOWARD MORE EFFICIENT AND MORE ETHICAL
DESIGNS
The most ethical design possible would treat each patient at his
or her own specific MTD. Were we in a position to do that, of
course, no actual trial would be necessary. It is a lack of more
precise knowledge that requires us to carry out the dose finding
study. Even so, such an objective, even if wholly idealized and
theoretical, can shed light on our endeavour. Specifically, as our
knowledge improves, and it will do so in the course of any
study, then such knowledge should be used efficiently to deliver
a more accurate dose to the patient. Only the kind of models
employed by designs with memory can achieve this. As an
example, we can use prognostic information such as the degree
of prior treatment to obtain a more accurate dose allocation
for each patient (Geoerger et al, 2005). These ideas extend almost
immediately and enable us to include in a single study patients
with different prognoses, such as children and adults. Pursuing
the goal of better adapting the treatment to the specifics relating
to each individual patient, we can use pk/pd information
(Piantadosi et al, 1998). Finally, as the clinical situation of these
studies evolves and we make observations not just about toxicities,
but also on measures of responses, then we can target quantities
other than the MTD, in particular the MSD (the most successful
dose), which combines information on toxicities and responses
together. Only designs with memory can underwrite such studies
and we believe that memoryless designs should be gradually
phased out of use in the context of phase I and phase I/II dose-
finding studies.
REFERENCES
Bos AM, De Vos FY, de Vries EG, Beijnen JH, Rosing H, Mourits MJ,
van der Zee AG, Gietema JA, Willemse PH (2005) A phase I study
of intraperitoneal topotecan in combination with intravenous
carboplatin and paclitaxel in advanced ovarian cancer. Eur J Cancer 41:
539–548
Faries D (1994) Practical modifications of the continual reassessment
method for phase I cancer clinical trials. J Biopharmac Stat 4: 147–164
Gasparini M, Eisele J (2000) A curve-free method for phase I clinical trials.
Biometrics 56: 609–615
Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D,
Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK (2004) A phase I
study of AMD473 and docetaxel given once every 3 weeks in patients
with advanced refractory cancer: a National Cancer Institute of Canada-
Clinical Trials Group trial, IND 131. Ann Oncol 15: 1115–1122
Geoerger B, Vassal G, Doz F, O’Quigley J, Wartelle M, Watson AJ, Raquin
MA, Frappaz D, Chastagner P, Gentet JC, Rubie H, Couanet D, Geoffray
A, Djafari L, Margison GP, Pein F (2005) Dose finding and O(6)-
alkylguanine-DNA alkyltransferase study of cisplatin combined with
temozolomide in paediatric solid malignancies. Br J Cancer 93:
529–537
Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda
WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM
(2004) Phase I and pharmacokinetic study of a low-clearance,
unilamellar liposomal formulation of lurtotecan, a topoisomerase 1
inhibitor, in patients with advanced leukemia. Cancer 100: 1449–1458
Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improve-
ments in the continual reassessment method for phase I studies. Stat
Med 14: 1149–1161
Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM
(1994) A comparison of two phase I trial designs. Stat Med 13:
1799–1806
Levy V, Zohar S, Porcher R, Chevret S (2001) Alternate designs for conduct
and analysis of phase I cancer trials. Blood 98: 1275–1276
O’Quigley J (2005) Retrospective analysis of sequential dose-finding
designs. Biometrics 61: 749–756
O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a
practical design for phase 1 clinical trials in cancer. Biometrics 46: 33–48
O’Quigley J, Shen LZ (1996) Continual reassessment method: a likelihood
approach. Biometrics 52: 673–684
Okamoto I, Hamada A, Matsunaga Y, Sasaki JI, Fujii S, Uramoto H,
Yamagata H, Mori I, Kishi H, Semba H, Saito H (2006) Phase I and
pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline,
in patients with refractory or relapsed lung cancer. Cancer Chemother
Pharmacol 57: 282–288
Piantadosi S, Fisher JD, Grossman S (1998) Practical implementation of a
modified continual reassessment method for dose-finding trials. Cancer
Chemother Pharmacol 41: 429–436
Reiner E, Paoletti X, O’Quigley J (1999) Operating characteristics of the
standard phase I clinical trial design. Comput Stat Data Anal 30:
303–315
Experimental designs for phase I and phase I/II dose-finding studies
J O’Quigley and S Zohar
613
British Journal of Cancer (2006) 94(5), 609–613 & 2006 Cancer Research UK